Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05244304 · ClinicalTrials.gov registry record · Phase 3
Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease
A Phase 3 study, sponsored by Belite Bio.
- Completed
- Registry status
- Phase 3
- Development phase
- 104
- Enrollment target
NCT05244304 is a Phase 3 study that has completed, run by Belite Bio. The registered enrollment target is 104 participants.
The verdict
NCT05244304, a Phase 3 study, has completed, sponsored by Belite Bio.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 104 participants
- Enrollment target
Study Summary
The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
Interventions
- DRUG Placebo
- DRUG Tinlarebant
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 104 participants |
| Start Date | 2022-03-28 |
| Est. Completion | 2025-09-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05244304
The ClinicalTrials.gov registry entry for NCT05244304 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 104 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Belite Bio, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT05244304 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05244304 about?
NCT05244304 is a clinical study titled "Phase 3, Randomized, Placebo-Controlled Study of Tinlarebant to Explore Safety and Efficacy in Adolescent Stargardt Disease". The primary objective of this trial is to assesses the efficacy of tinlarebant in slowing the rate of growth of atrophic lesion(s) in adolescent subjects with STGD1
What is the current status of trial NCT05244304?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 104 participants. The study started on 2022-03-28. Estimated completion is 2025-09-12.
What interventions are being tested in trial NCT05244304?
The interventions under investigation include: Placebo (DRUG), Tinlarebant (DRUG).
Who is sponsoring clinical trial NCT05244304?
This trial is sponsored by Belite Bio, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.